Clara Hjalmarsson

MD PhD

Sahlgrenska universitetssjukhuset
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Year:

2026

Despite its low diagnostic yield, endomyocardial biopsy (EMB) remains the gold standard for establishing a definitive diagnosis in many cardiomyopathies. We developed and validated a machine-learning–based score to predict the likelihood of diagnostic EMB using non-invasive data. We retrospectively analyzed 775 heart failure patients who underwent EMB. A random forest algorithm was selected for score development based on superior discriminative performance. The model was externally validated in an independent cohort ( n = 171). The study population was predominantly male (72.1%), with half of the patients in NYHA class III–IV. EMB yielded a definitive diagnosis in 19.9% of cases, most commonly amyloidosis (50%). A predictive score (0-100 range) was derived from key non-invasive predictors. Right ventricular late gadolinium enhancement (LGE) on cardiac magnetic resonance emerged as the strongest predictor, followed by left ventricular and atrial LGE, NTproBNP levels, and renal function. The model demonstrated excellent discrimination, with an area under the curve of 0.92 (95% CI = 0.89–0.96) in cross-validation and 0.91 (95% CI = 0.86–0.98) in the testing set, with consistent performance on external validation (AUC 0.82, 95% CI = 0.76–0.89). This machine-learning-based score may provide a non-invasive tool to support EMB decision-making in clinical practice.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Atrial fibrillation (AF) is suggested to be associated with venous thromboembolism (VTE) and might thereby play a role in the development of chronic thromboembolic pulmonary hypertension (PH). By elevating left‐sided filling pressure and promoting atrial myopathy, AF may also play a role in the development of postcapillary PH. We aimed to investigate the association between AF, with or without incident VTE, and the occurrence of PH. Methods A total of 521 988 patients diagnosed with AF between 1987 and 2013, without a previous diagnosis of VTE or PH, were identified from the Swedish National Patient Register and matched for age, sex, and county with 1 017 277 population controls without AF, VTE, or PH. Results The mean age of the patients with AF was 71.1 (SD ±10.1) years and 42.8% were women. During a median follow‐up period of 11 (interquartile range 5.1–17) years, 4454 (0.9%) patients with AF, and 1855 (0.2%) controls were diagnosed with PH, hazard ratio 4.7 (4.4–5.0). The AF group had a significantly higher comorbidity burden at baseline, with a mean CHA 2 DS 2 ‐VASc of 2.9 compared with 2.1 in controls. In the absence of intercurrent VTE, the hazard ratio of PH was 4.2 (3.9–4.5) among patients with AF compared with controls. Intercurrent VTE increased the hazard ratio of PH a further 1.9‐fold (1.7–2.1) and 3.5 (3.1–4.0), among patients with AF and controls, respectively. The hazard ratio for PH in patients with AF with incident VTE was 8.1 (7.3–9.1). Conclusions AF was associated with a markedly increased risk of developing incident PH, and this risk was further increased by incident VTE.

Year:

2025

Aims Acute myocarditis (AM) is a disease with variable prognosis, ranging from complete recovery to end-stage heart failure (HF) and death but often challenging to differentiate from unexplained acute chest pain (UCP) in the acute setting. This study examines the short-tem and long-term outcomes of AM compared with UCP, focusing on the risk of HF development. Methods We used the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies-registry to identify patients >16 years admitted to hospital between 1 January 1998 and 31 December 2018 with either AM or UCP. Patients were followed for outcomes including mortality, rehospitalisation and HF development over both short-term (30 days) and long-term periods. Cox proportional hazards models were used to compare the risks, adjusting for demographic and clinical-related factors. Results A total of 3792 patients with AM and 109 934 patients with UCP were included. Median follow-up time was 7.8 years (Q1, Q3; 3.4, 12.3). AM patients were younger compared with UCP patients, median age 37 years (Q1, Q3; 26, 52) vs 59 years (Q1, Q3; 49, 69) and more likely to be men (79.9% vs 51.4%, p<0.001). Comorbidity burden was less pronounced within the AM cohort. Chest pain was the most common presenting symptom in both groups. Mortality rate at 30 days (OR 3.75, 95% CI 1.9 to 7.3, p<0001) as well as long term (OR 2.0, 95% CI 1.69 to 2.39, p<0.001) were significantly higher in AM patients compared with UCP. AM patients were more likely to develop HF during follow-up (OR 2.3, 95% CI 1.81 to 2.93, p<0001). Conclusions AM is associated with worse short-term and long-term outcomes compared with UCP, including a higher risk of developing HF even after the first year.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Elmir Omerovic

Chair Professor of Cardiology

University of Gothenburg

SWEDEN
View details

Annika Rosengren

University of Gothenburg

SWEDEN
View details

Martin Lindgren

Associate professor

University of Gothenburg

SWEDEN
View details

J. Gustav Smith

-

SWEDEN
View details

Emanuele Bobbio

Sahlgrenska universitetssjukhuset

SWEDEN
View details

José González-Costello

University of Barcelona

SPAIN
View details

Alberto Giannoni

Researcher (type-B)

Scuola Superiore Sant'Anna

ITALY
View details

Christian Lars Polte

Karolinska University Hospital

SWEDEN
View details

Mark Petrie

University of Glasgow

UNITED KINGDOM
View details

Giulio Savonitto

University of Udine

ITALY
View details

Marish I. F. J. Oerlemans

Cardiologist

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Alastair Moss

British Heart Foundation Academic Clinical Lecturer

University of Leicester

UNITED KINGDOM
View details

Italo Porto

Full Professor of Cardiovascular Diseases

University of Genoa

ITALY
View details

Sandeep Sahay

Associate Professor

Texas A&M University

UNITED STATES
View details

Entela Bollano

-

SWEDEN
View details